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2 Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL et al. Polycomb recessive complex 2 (PRC2) is an epigenetic regulator that marks repressive chromatin domain through trimethylation of histone H3 lysine 27 (H3K27). 1, 2 Recently, inactivating mutations of EZH2, the catalytic subunit of PRC2, have been identified in subsets of myeloid disorders including myelodysplastic syndrome (MDS), and are predicted to inactivate PRC2 function.
3-5 PRC2 comprises four core components, EZH2, EED, SUZ12 and RBBP4 (also known as RbAp48). Although EZH2 possesses the methyltransferase activity of PRC2, EZH2 is inactive on its own, and direct interaction of EED to EZH2 is required for EZH2 to fully exert its enzymatic activity. 1, 2, 6 In addition, EED binds to trimethylated H3K27 (H3K27me3) through the so-called 'aromatic cage' composed of three aromatic amino acids (Phe97, Trp364 and Tyr365) to activate PRC2. 1, 7 A previous report demonstrated that PRC2 complexes possessing an aromatic-cage mutation in EED show severely reduced enzymatic activities in the presence of H3K27me3 peptides. 7 EED haploinsufficiency (Leu196Pro) in mice leads spontaneously to a myeloproliferative disorder, 8 and exposure of hypomorphic (Ile193Asn) homozygotes to genotoxic stresses gives rise to tumorigenesis. 8, 9 These findings strongly suggest that dysfunction of EED might be involved in the pathogenesis of myeloid disorders. Here we searched for EED mutations in MDS and related diseases.
The genomic regions encompassing the EED gene (NCBI accession number NM_003797.2) were sequenced in bone marrow samples obtained from 192 patients with MDS or related diseases ( Figure 1a ). Detailed clinical information of individual samples was given in our previous report. 10 We identified EED mutations in six cases ( Figure 1a and Supplementary Table 1), which were confirmed by repeated amplification and sequencing. None of these mutations are reported in the 1000 genomes database (a deep catalog of human genetic variation) 11 and the Ensemble gene and the transcript sequences currently available. We were unable to evaluate whether the mutations arose from germline or somatic tissues or to examine mRNA expression patterns, due to limited sample availability. Of note, three of the six mutations occurred in patients with chronic myelomonocytic leukemia (CMML) or acute myelogenous leukemia possibly preceded by CMML (Figure 1a ). This is consistent with the finding that EZH2 abnormalities are most common in CMML and MDS/ myelodysplastic-myeloproliferative neoplasms (MDS/MPN). 4 In addition, we observed no compound mutations of the EED and Letters to the Editor EZH2 genes (Figure 2a ), strongly suggesting that these genes may independently affect PRC2 function.
Two distinct mutations lacking a part of intron 5 and the entire exon 6 were found in individuals with CMML1 and refractory anemia with excess blasts 2 (RAEB2) (U31 and U187, respectively) ( Figure 1a ). In these patients, exon 5 should be either spliced to exon 7 or followed by intron 5, and in each case consequently creates a new stop codon; therefore the mutations are predicted to produce proteins lacking part of the WD40 II motif and all of the WD40 motifs III-V (hereafter referred to as the DC185 mutant) (Figure 1a) . A genomic region containing exon 5 was absent in an acute myelogenous leukemia (M4) patient with myelodysplasia-related changes arising from CMML (U107) (Figure 1a) . In U107 subject, exon 4 should be followed by exon 6 in frame; therefore, the corresponding protein product (hereafter referred to as the D143-184 mutant) lacks part of the first and second WD40 repeats (Figure 1a) . One refractory cytopenia with unilineage dysplasia subject (U121) possessed a missense mutation (T719A; CTA4CAA), producing a Leu363Gln amino-acid substitution (hereafter referred to as the L240Q mutant) (Figure 1a ). In addition, another CMML1 subject (U161) possessed a missense mutation (T1089G; ATT4ATG), producing an Ile363Met amino-acid substitution (hereafter referred to as the I363M mutant) (Figure 1a) . The exon 11 deletion in another refractory cytopenia with unilineage dysplasia subject (U198) is predicted to produce an EED protein that lacks one and a half of the WD40 repeat motifs located at the C terminus (hereafter referred to as the DC376-441 mutant), as exon 10 should be followed by exon 12 with premature stop (c) Interaction of EZH2 with EEDs. 293T cells were transfected with plasmids expressing the proteins indicated. The amounts of plasmids were adjusted to achieve similar protein expression levels at the stage of transfection. Cell lysates were immunoprecipitated and analyzed by western blot using anti-Flag (EZH2) and anti-Myc (EED) antibodies. Input represents 0.5% or 2% of cell lysate used for IP (Myc or Flag, respectively). IgL, immunoglobulin light chain. (d) I363M mutant decreases global H3K27me3 levels through impaired interaction to H3K27me3. Left: The alignment of amino-acid sequences surrounding Ile363. Blue-shaded boxes indicate well-conserved aromatic cage residues. The yellow-shaded box indicates the Ile363Met mutation found in subject U161 CMML. (Protein DataBank ID code: 3IIW). The boxed area is magnified on the right side. Middle: Myc-tagged wild-type EED (WT) or I363M mutant was co-expressed with Flag-tagged EZH2 in 293T cells. Cell lysates were analyzed in a pull-down assay using H3K27me3 peptide by western blot using an anti-Myc antibody. Input represents 0.5% of cell lysate used for the pull-down assay. Relative binding efficiencies (WT ¼ 1) were estimated by normalizing the densitometry values representing the bound EED against those from the 'Input EED' . Bar graph: mean binding±s.e. from three independent experiments. *P ¼ 0.0028 (Student's t-test). Right: Myc-tagged wild-type EED (WT) or I363M mutant was retrovirally transduced in NIH3T3 cells. Acid-extracted histones were analyzed by western blot using an anti-H3K27me3 or an anti-total H3. codon (Figure 1a) . In subjects with a deletion (U31, U107, U187 and U198), the deletion points demonstrated the joining of the 5 0 part and 3 0 part with 1-to 8-base-pair microhomology (Figure 1a) , which suggests the possibility that these deletions resulted from recombination with unequal crossover. 12 We first evaluated the cellular expression levels of the mutant proteins following forced expression in 293T cells. The result showed that exon deletions (DC185, D143-184, L240Q and DC376-441) and L240Q mutant expressed significantly less protein than did either the wild-type or I363M (Figure 1b, top, indicated by  arrowheads) , despite a similar level of expression of the corresponding mRNAs (Figure 1b, bottom) . These results indicate that the exon deletions and L240Q impaired translation and/or stability of the EED proteins, and suggest that these mutated forms are hypomorphic, and thus are functionally defective. Interaction of EED with EZH2 was demonstrated to be necessary for the full activity of PRC2; 2 hence we next examined the binding ability of the mutant proteins to EZH2. As expected from the results of the previous studies showing that WD repeats are important for EED-EZH2 interaction, 6,13 the DC185, D143-184 and DC376-441 failed to bind to EZH2 (Figure 1c) . L240Q, in contrast, showed comparable binding ability to EZH2 as compared with wild-type EED. Thus, these results suggest that exon deletions and an L240Q mutation disrupt the functional integrity of PRC2, owing to poor protein expression coupled with or without their inability to bind EZH2.
On the other hand, the I363M mutant retained the ability to bind EZH2 and was expressed at a level similar to that of the wildtype EED (Figures 1b and c) , suggesting that this mutant could incorporate into the PRC2 complex comparably with the wild type. However, substitution of an amino acid in such close proximity to the cage residues raised the possibility that it might affect the EED-H3K27me3 interaction, and therefore PCR2 function (Figure 1d, left) . 7 We compared the binding of wild-type and I363M mutant EED in a pull-down assay that employed a synthetic H3K27me3 peptide ligand. Intriguingly, the I363M substitution significantly inhibited the EED-H3K27me3 interaction when coexpressed in the presence of EZH2 (Figure 1d, middle) . In addition, global H3K27me3 levels were severely decreased in cells stably overexpressing the I363M mutant (Figure 1d, right) , suggesting that the PRC2 complex incorporating the I363M mutant is functionally compromised, possibly through impaired structural integrity of the aromatic cage.
In summary, all the six mutated forms of EED displayed functional defects involving changes: (i) protein stability, (ii) interaction with EZH2 and/or (iii) binding to H3K27me3, thereby impairing PRC2 function (Figure 2b) . We suggest that, in addition to inactivating mutations of catalytic EZH2, [3] [4] [5] non-catalytic EED mutations exclusively perturb PRC2-mediated epigenetic regulation and substantially contribute to the pathogenesis of MDS and related diseases (Figure 2b) . Recently, Score et al.
14 reported a set of defective gene mutations of PRC2 constituents, including an EED point mutation, Gly255Asp, in 148 MDS/MPN cases. Our data suggest that various types of defective EED mutations contribute to the MDS pathogenesis. Analysis of more samples would clarify the clinical features of patients with EED mutation(s) in MDS and related diseases. Our findings highlight that recurrent mutations in PRC2 may constitute a new molecular-based disease category of myeloid malignancies.
